Compare BBCP & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBCP | CBIO |
|---|---|---|
| Founded | 1983 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.1M | 553.9M |
| IPO Year | 2017 | 2013 |
| Metric | BBCP | CBIO |
|---|---|---|
| Price | $9.08 | $12.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $13.50 | ★ $31.50 |
| AVG Volume (30 Days) | 131.8K | ★ 475.6K |
| Earning Date | 09-03-2026 | 11-05-2026 |
| Dividend Yield | ★ 5.70% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $392,867,000.00 | $18,500.00 |
| Revenue This Year | $9.73 | N/A |
| Revenue Next Year | $5.12 | $177.36 |
| P/E Ratio | $130.29 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.56 | $8.72 |
| 52 Week High | $12.19 | $27.41 |
| Indicator | BBCP | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 40.34 | 30.38 |
| Support Level | $8.89 | $10.36 |
| Resistance Level | $9.64 | $13.41 |
| Average True Range (ATR) | 0.31 | 1.06 |
| MACD | -0.07 | -0.13 |
| Stochastic Oscillator | 29.03 | 9.66 |
Concrete Pumping Holdings Inc is a provider of concrete pumping services and concrete waste management services in the fragmented United States and United Kingdom markets. Its large fleet of specialized pumping equipment and trained operators enables it to deliver concrete placement solutions. The company's operating segments include U.S. Concrete Pumping, U.K. Operations, and U.S. Concrete Waste Management Services, with the majority of revenue generated from the U.S. Concrete Pumping segment. Geographically, it operates in the United States and the United Kingdom, generating majority of its revenue from the United States.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.